Product image of Melkart (Vildagliptin) supplied by GNH India

Melkart

Active Ingredient:
Vildagliptin
Origin:
EU

Melkart (Vildagliptin)

Vildagliptin, the active ingredient in Melkart, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when combined with diet and exercise.

GNH India supplies Melkart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides reliable global distribution, and manufactures products under GMP conditions for bulk procurement.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Vildagliptin is used in the treatment of type 2 diabetes mellitus, targeting the incretin pathway to improve glucose regulation.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as a single agent.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin or other oral antidiabetics.
  • Type 2 diabetes mellitus (adjunct to insulin): reduces insulin requirements and helps achieve target HbA1c.

How It Works

  • Vildagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous incretin levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and overall glycaemic control.

Side Effects

Vildagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate discomfort in the stomach.
  • Headache: transient tension‑type headache.
  • Dizziness: occasional light‑headedness.
  • Upper respiratory tract infection: symptoms of common cold.
  • Nasopharyngitis: irritation of the nasal passages.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.
  • Severe hypoglycaemia: prolonged low blood glucose, especially with other hypoglycaemic agents.

Precautions & Warnings

When prescribing Vildagliptin, clinicians should consider several safety aspects to minimise risk.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: monitor liver enzymes regularly.
  • Elderly patients: watch for hypoglycaemia, especially with concomitant sulfonylureas.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
  • Drug interactions: review all concomitant medications for possible additive hypoglycaemic effect.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Vildagliptin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Insulin: may cause severe hypoglycaemia.
  • Sulfonylureas (e.g., glimepiride): increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce plasma concentrations of Vildagliptin.
  • Diuretics: may affect glucose homeostasis.
  • ACE inhibitors: monitor renal function and potassium levels.

Frequently Asked Questions

Melkart contains vildagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels when used together with diet, exercise and, when appropriate, other antidiabetic medicines.

Vildagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to better post‑prandial and overall glycaemic control.

The appropriate dose of Melkart is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Dosage adjustments may be required for patients with renal impairment.

Safety of vildagliptin in pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To request Melkart, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Melkart (vildagliptin) shares the same class mechanism as other DPP‑4 inhibitors such as sitagliptin or linagliptin. Differences may lie in dosing frequency, renal adjustment requirements and specific safety profiles, but all aim to improve glycaemic control by enhancing incretin activity.

Melkart tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Melkart is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events associated with vildagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, hepatic dysfunction, and rare skin disorders like Stevens‑Johnson syndrome. Any sudden abdominal pain, rash, or signs of liver injury should prompt immediate medical evaluation.

Melkart should be avoided in individuals with known hypersensitivity to vildagliptin or any excipients, in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted, and in those with a history of pancreatitis unless specifically advised by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT